Evidence map›Paper›PMID 39172771›Full record

ArticlePloS one2024

Robust isolation protocol for mouse leukocytes from blood and liver resident cells for immunology research.

Dorien De Pooter, Ben De Clerck, Koen Dockx, Domenica De Santis, Sarah Sauviller, Pascale Dehertogh, Matthias Beyens, Isabelle Bergiers, Isabel Nájera, Ellen Van Gulck and 2 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dorien De PooterInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Ben De ClerckInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Koen DockxCharles River Laboratories, Beerse, Belgium.
Domenica De SantisCharles River Laboratories, Beerse, Belgium.
Sarah SauvillerInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Pascale DehertoghInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Matthias BeyensDiscovery Technologies & Molecular Pharmacology, Therapeutics Discovery, Janssen Research and Development, Beerse, Belgium.
Isabelle BergiersDiscovery Technologies & Molecular Pharmacology, Therapeutics Discovery, Janssen Research and Development, Beerse, Belgium.ORCID 0000-0001-9622-7960
Isabel NájeraInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, California, Brisbane, United States of America.
Ellen Van GulckInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Nádia Conceição-NetoInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.ORCID 0000-0002-9659-6835
Wim PiersonInfectious Diseases Discovery, Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.ORCID 0000-0003-1369-4606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research on liver-related conditions requires a robust and efficient method to purify viable hepatocytes, lymphocytes and all other liver resident cells, such as Kupffer or liver sinusoidal endothelial cells. Here we describe a novel purification method using liver enzymatic digestion, followed by a downstream optimized purification. Using this enzymatic digestion protocol, the resident liver cells as well as viable hepatocytes could be captured, compared to the classical mechanical liver disruption method. Moreover, single-cell RNA-sequencing demonstrated higher quality lymphocyte data in downstream analyses after the liver enzymatic digestion, allowing for studying of immunological responses or changes. In order to also understand the peripheral immune landscape, a protocol for lymphocyte purification from mouse systemic whole blood was optimized, allowing for efficient removal of red blood cells. The combination of microbeads and mRNA blockers allowed for a clean blood sample, enabling robust single-cell RNA-sequencing data. These two protocols for blood and liver provide important new methodologies for liver-related studies such as NASH, hepatitis virus infections or cancer research but also for immunology where high-quality cells are indispensable for further downstream assays.

Indexed as

LeukocytesLiverAnimalsCell SeparationHepatocytesLymphocytesMaleMiceMice, Inbred C57BLSingle-Cell Analysis

Identifiers

PMID39172771
PMCPMC11340898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.